Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the ‘intermediate’ range. This paper investigated the relationship bet...
Uložené v:
| Vydané v: | BMC medicine Ročník 19; číslo 1; s. 184 - 11 |
|---|---|
| Hlavní autori: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
20.08.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1741-7015, 1741-7015 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the ‘intermediate’ range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D.
Methods
We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model.
Results
The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (
n
= 2358/4224) of participants classified ‘high-risk’ with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (
n
= 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44–47 mmol/mol [6.2–6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39–41 mmol/mol (5.7–5.9%) and 7.0% (5.4, 8.6%) for 42–43 mmol/mol (6.0–6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7–6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%).
Conclusions
A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. |
|---|---|
| AbstractList | Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the 'intermediate' range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. Methods We studied 4227 participants without diabetes aged [greater than or equai to] 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c [greater than or equai to] 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. Results The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified 'high-risk' with HbA1c [greater than or equai to] 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c [greater than or equai to] 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44-47 mmol/mol [6.2-6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39-41 mmol/mol (5.7-5.9%) and 7.0% (5.4, 8.6%) for 42-43 mmol/mol (6.0-6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7-6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). Conclusions A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Keywords: Non-insulin treated type 2 diabetes, Progression, Disease prevention, Cohort analysis, EXTEND, Pre-diabetes, HbA1c, Intermediate hyperglycaemia Abstract Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the ‘intermediate’ range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. Methods We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. Results The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified ‘high-risk’ with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44–47 mmol/mol [6.2–6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39–41 mmol/mol (5.7–5.9%) and 7.0% (5.4, 8.6%) for 42–43 mmol/mol (6.0–6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7–6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). Conclusions A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the 'intermediate' range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified 'high-risk' with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44-47 mmol/mol [6.2-6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39-41 mmol/mol (5.7-5.9%) and 7.0% (5.4, 8.6%) for 42-43 mmol/mol (6.0-6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7-6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the 'intermediate' range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. We studied 4227 participants without diabetes aged [greater than or equai to] 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c [greater than or equai to] 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified 'high-risk' with HbA1c [greater than or equai to] 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c [greater than or equai to] 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44-47 mmol/mol [6.2-6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39-41 mmol/mol (5.7-5.9%) and 7.0% (5.4, 8.6%) for 42-43 mmol/mol (6.0-6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7-6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the 'intermediate' range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D.BACKGROUNDType 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the 'intermediate' range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D.We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model.METHODSWe studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model.The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified 'high-risk' with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44-47 mmol/mol [6.2-6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39-41 mmol/mol (5.7-5.9%) and 7.0% (5.4, 8.6%) for 42-43 mmol/mol (6.0-6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7-6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%).RESULTSThe overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified 'high-risk' with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44-47 mmol/mol [6.2-6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39-41 mmol/mol (5.7-5.9%) and 7.0% (5.4, 8.6%) for 42-43 mmol/mol (6.0-6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7-6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%).A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D.CONCLUSIONSA large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the ‘intermediate’ range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. Methods We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. Results The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% (n = 2358/4224) of participants classified ‘high-risk’ with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% (n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44–47 mmol/mol [6.2–6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39–41 mmol/mol (5.7–5.9%) and 7.0% (5.4, 8.6%) for 42–43 mmol/mol (6.0–6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7–6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). Conclusions A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these programmes is usually determined by a measure of glycaemia in the ‘intermediate’ range. This paper investigated the relationship between HbA1c and future diabetes risk and determined the impact of varying thresholds to identify those at high risk of developing T2D. Methods We studied 4227 participants without diabetes aged ≥ 40 years recruited to the Exeter 10,000 population cohort in South West England. HbA1c was measured at study recruitment with repeat HbA1c available as part of usual care. Absolute risk of developing diabetes within 5 years, defined by HbA1c ≥ 48 mmol/mol (6.5%), according to baseline HbA1c, was assessed by a flexible parametric survival model. Results The overall absolute 5-year risk (95% CI) of developing T2D in the cohort was 4.2% (3.6, 4.8%). This rose to 7.1% (6.1, 8.2%) in the 56% ( n = 2358/4224) of participants classified ‘high-risk’ with HbA1c ≥ 39 mmol/mol (5.7%; ADA criteria). Under IEC criteria, HbA1c ≥ 42 mmol/mol (6.0%), 22% ( n = 929/4277) of the cohort was classified high-risk with 5-year risk 14.9% (12.6, 17.2%). Those with the highest HbA1c values (44–47 mmol/mol [6.2–6.4%]) had much higher 5-year risk, 26.4% (22.0, 30.5%) compared with 2.1% (1.5, 2.6%) for 39–41 mmol/mol (5.7–5.9%) and 7.0% (5.4, 8.6%) for 42–43 mmol/mol (6.0–6.1%). Changing the entry criterion to prevention programmes from 39 to 42 mmol/mol (5.7–6.0%) reduced the proportion classified high-risk by 61%, and increased the positive predictive value (PPV) from 5.8 to 12.4% with negligible impact on the negative predictive value (NPV), 99.6% to 99.1%. Increasing the threshold further, to 44 mmol/mol (6.2%), reduced those classified high-risk by 59%, and markedly increased the PPV from 12.4 to 23.2% and had little impact on the NPV (99.1% to 98.5%). Conclusions A large proportion of people are identified as high-risk using current thresholds. Increasing the risk threshold markedly reduces the number of people that would be classified as high-risk and entered into prevention programmes, although this must be balanced against cases missed. Raising the entry threshold would allow limited intervention opportunities to be focused on those most likely to develop T2D. |
| ArticleNumber | 184 |
| Audience | Academic |
| Author | Jones, Angus Hattersley, Andrew T. Dennis, John M. Rodgers, Lauren R. Hill, Anita V. Andrews, Rob C. Shields, Beverley M. Craig, Zoe May, Benedict McDonald, Timothy J. |
| Author_xml | – sequence: 1 givenname: Lauren R. orcidid: 0000-0002-5040-3073 surname: Rodgers fullname: Rodgers, Lauren R. email: L.R.Rodgers@exeter.ac.uk organization: Institute of Health Research, University of Exeter Medical School – sequence: 2 givenname: Anita V. surname: Hill fullname: Hill, Anita V. organization: NIHR Exeter Clinical Research Facility, Royal Devon & Exeter NHS Foundation Trust & University of Exeter Medical School – sequence: 3 givenname: John M. surname: Dennis fullname: Dennis, John M. organization: Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter – sequence: 4 givenname: Zoe surname: Craig fullname: Craig, Zoe organization: Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds – sequence: 5 givenname: Benedict surname: May fullname: May, Benedict organization: College of Mathematics Engineering and Physical Science, University of Exeter – sequence: 6 givenname: Andrew T. surname: Hattersley fullname: Hattersley, Andrew T. organization: Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation Trust – sequence: 7 givenname: Timothy J. surname: McDonald fullname: McDonald, Timothy J. organization: Academic Department of Blood Sciences, Royal Devon and Exeter NHS Foundation Trust – sequence: 8 givenname: Rob C. surname: Andrews fullname: Andrews, Rob C. organization: Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter – sequence: 9 givenname: Angus surname: Jones fullname: Jones, Angus organization: Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter – sequence: 10 givenname: Beverley M. surname: Shields fullname: Shields, Beverley M. organization: Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34412655$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksuO0zAYhSM0iLnAC7BAlpAQmw524kvCAqmqgBlpJDawthxfEpfELrbTUR-Ft8Vth9KO0ChKbNnfOb_951wWZ847XRSvEbxGqKYfIiobRGewRPmFBM_unxUXiGE0YxCRs6P5eXEZ4xLCkjCGXxTnFcaopIRcFL8XvbdSA2_ATTtHEqQ-6Nj7QQHjA7BKu2TNxroOWKfs2qpJDBGIBHrb9SDY-HOrTZuVBiVQVrQ66bzvFLDjarBSJOtd3JkddldBr7e-3uWp74IYRx0_AgGk731IIKZJbV4Wz00upV89jFfFjy-fvy9uZnffvt4u5nczSas65S9GTYMajKEWlEFtWimkaaliStVQY8IqbWqBjBSGamUoMxo1JYKqVAar6qq43fsqL5Z8FewowoZ7YfluwYeOi5CsHDQXjFLVStJKJDBBSFRGGEWorElZVQ3NXp_2XqupHbWS-ZJBDCempzvO9rzza15XjDU1zAbvHwyC_zXpmPhoo9TDIJz2U-QloRUuKYIso28foUs_BZdblSmGcQ23hzpQncgXsM74XFduTfmcMlLiirAmU9f_ofKj9GhlTp2xef1E8O5I0GsxpD76Ydr97FPwzXFHDq34m8AMlHtABh9j0OaAIMi3Mef7mPMcc76LOb_PovqRSNq0S1o-tx2ellZ7acx1XKfDv7Y9ofoDVx4ThA |
| CitedBy_id | crossref_primary_10_3389_fendo_2022_935016 crossref_primary_10_1038_s42255_025_01372_0 crossref_primary_10_7759_cureus_82464 crossref_primary_10_1016_j_numecd_2023_02_022 crossref_primary_10_1016_j_clinpr_2025_100494 crossref_primary_10_1016_j_atherosclerosis_2023_117285 crossref_primary_10_3390_ijms25105331 crossref_primary_10_1177_19322968251376380 |
| Cites_doi | 10.1111/j.1464-5491.2010.03037.x 10.1186/s12966-019-0877-3 10.2337/diacare.25.12.2165 10.1016/j.diabres.2018.02.023 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO;2-R 10.1016/S2213-8587(15)00291-0 10.1016/S2213-8587(15)70015-X 10.2337/dc13-0497 10.1136/bmj.39063.689375.55 10.2337/dc09-1843 10.1136/bmj.i6538 10.2337/dc09-2326 10.1136/bmj.h4717 10.1186/s12913-019-4809-3 10.1007/s00125-013-2902-4 10.1136/bmj.g2867 10.1177/2047487319880041 10.1016/j.diabres.2011.06.003 10.1016/j.diabres.2011.12.004 10.1056/NEJMoa012512 10.1002/14651858.CD012661.pub2. 10.1016/S2213-8587(19)30058-0 10.1016/j.diabres.2010.06.008 10.1136/bmjopen-2016-014953 10.1136/bmjopen-2017-017184 10.1002/pdi.2080 10.1016/S0140-6736(12)60283-9 10.2337/dc07-2162 10.1016/S0140-6736(16)00618-8 10.1186/s12916-016-0570-1 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-021-02054-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_a766dbc5bc1a4511a3fafd56c8523396 PMC8377980 A675243579 34412655 10_1186_s12916_021_02054_w |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England United Kingdom United Kingdom--UK Australia |
| GeographicLocations_xml | – name: England – name: United Kingdom – name: United Kingdom--UK – name: Australia |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MR/N00633X/1 – fundername: Medical Research Council grantid: MR/K005707/1 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-c6419919440ea670efbcacfb6d7dd80e4573ef8a1fcaf6edf67fe19210d2df4d3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000686770600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1741-7015 |
| IngestDate | Fri Oct 03 12:44:29 EDT 2025 Tue Nov 04 01:45:58 EST 2025 Sun Nov 09 09:15:50 EST 2025 Wed Oct 08 14:21:10 EDT 2025 Tue Nov 11 10:35:58 EST 2025 Tue Nov 04 18:08:24 EST 2025 Thu May 22 21:20:20 EDT 2025 Mon Jul 21 06:03:07 EDT 2025 Sat Nov 29 04:08:23 EST 2025 Tue Nov 18 21:07:02 EST 2025 Sat Sep 06 07:29:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Progression Disease prevention Cohort analysis Non-insulin treated type 2 diabetes EXTEND Pre-diabetes Intermediate hyperglycaemia HbA1c |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-c6419919440ea670efbcacfb6d7dd80e4573ef8a1fcaf6edf67fe19210d2df4d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5040-3073 |
| OpenAccessLink | https://www.proquest.com/docview/2574480523?pq-origsite=%requestingapplication% |
| PMID | 34412655 |
| PQID | 2574480523 |
| PQPubID | 42775 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a766dbc5bc1a4511a3fafd56c8523396 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377980 proquest_miscellaneous_2563426107 proquest_journals_2574480523 gale_infotracmisc_A675243579 gale_infotracacademiconefile_A675243579 gale_healthsolutions_A675243579 pubmed_primary_34412655 crossref_primary_10_1186_s12916_021_02054_w crossref_citationtrail_10_1186_s12916_021_02054_w springer_journals_10_1186_s12916_021_02054_w |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-20 |
| PublicationDateYYYYMMDD | 2021-08-20 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medicine |
| PublicationTitleAbbrev | BMC Med |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | E Barry (2054_CR6) 2017; 356 2054_CR28 MI Schmidt (2054_CR24) 2019; 7 DL Christensen (2054_CR41) 2010; 33 2054_CR21 SJ Griffin (2054_CR19) 2000; 16 NH Cho (2054_CR1) 2018; 138 JR Smith (2054_CR36) 2019; 16 LJ Gray (2054_CR18) 2010; 27 X Zhuo (2054_CR37) 2013; 36 DH Morris (2054_CR22) 2013; 56 National Institute for Health and Care Excellence (2054_CR15) 2011 2054_CR29 J Stokes (2054_CR33) 2019; 19 World Health Organisation (2054_CR30) 2006 NJ Wareham (2054_CR10) 2015; 3 S Soulimane (2054_CR35) 2011; 96 J Lindström (2054_CR8) 2008; 31 2054_CR42 DM Nathan (2054_CR9) 2015; 3 B Kumaravel (2054_CR39) 2012; 96 2054_CR16 2054_CR14 NHS England (2054_CR27) 2016 2054_CR12 J Beulens (2054_CR23) 2019; 26 2054_CR32 P Chamnan (2054_CR34) 2011; 34 B Zhou (2054_CR2) 2016; 387 B Schöttker (2054_CR40) 2016; 14 The Diabetes Prevention Program (DPP) Research Group (2054_CR4) 2002; 25 CL Gillies (2054_CR5) 2007; 334 ES Kilpatrick (2054_CR20) 2014; 348 S Roberts (2054_CR13) 2017; 7 W Knowler (2054_CR7) 2002; 346 SA Mostafa (2054_CR25) 2010; 90 LJ Gray (2054_CR3) 2017; 34 E Barry (2054_CR11) 2015; 351 National Institute for Health and Care Excellence (2054_CR17) 2012 AG Tabák (2054_CR26) 2012; 379 2054_CR31 C Thomas (2054_CR38) 2017; 7 |
| References_xml | – ident: 2054_CR16 – volume: 27 start-page: 887 year: 2010 ident: 2054_CR18 publication-title: Diabet Med doi: 10.1111/j.1464-5491.2010.03037.x – volume-title: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia year: 2006 ident: 2054_CR30 – volume: 16 start-page: 112 issue: 1 year: 2019 ident: 2054_CR36 publication-title: Int J Behav Nutr Phys Act doi: 10.1186/s12966-019-0877-3 – volume: 25 start-page: 2165 year: 2002 ident: 2054_CR4 publication-title: Diabetes Care doi: 10.2337/diacare.25.12.2165 – volume: 138 start-page: 271 year: 2018 ident: 2054_CR1 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2018.02.023 – volume: 16 start-page: 164 issue: 3 year: 2000 ident: 2054_CR19 publication-title: Diabetes Metab Res Rev doi: 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO;2-R – volume: 3 start-page: 866 year: 2015 ident: 2054_CR9 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(15)00291-0 – volume: 3 start-page: 160 issue: 3 year: 2015 ident: 2054_CR10 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(15)70015-X – volume: 36 start-page: 3992 issue: 12 year: 2013 ident: 2054_CR37 publication-title: Diabetes Care doi: 10.2337/dc13-0497 – ident: 2054_CR29 – volume: 334 start-page: 299 issue: 7588 year: 2007 ident: 2054_CR5 publication-title: Br Med J doi: 10.1136/bmj.39063.689375.55 – volume: 33 start-page: 580 issue: 3 year: 2010 ident: 2054_CR41 publication-title: Diabetes Care doi: 10.2337/dc09-1843 – volume: 356 start-page: i6538 year: 2017 ident: 2054_CR6 publication-title: BMJ doi: 10.1136/bmj.i6538 – volume: 34 start-page: 950 issue: 4 year: 2011 ident: 2054_CR34 publication-title: Diabetes Care doi: 10.2337/dc09-2326 – ident: 2054_CR32 – ident: 2054_CR42 – volume: 351 start-page: h4717 year: 2015 ident: 2054_CR11 publication-title: BMJ doi: 10.1136/bmj.h4717 – volume-title: Type 2 diabetes prevention: population and community-level interventions. NICE guideline PH35 year: 2011 ident: 2054_CR15 – volume: 19 start-page: 1 issue: 1 year: 2019 ident: 2054_CR33 publication-title: BMC Health Serv Res doi: 10.1186/s12913-019-4809-3 – volume: 56 start-page: 1489 issue: 7 year: 2013 ident: 2054_CR22 publication-title: Diabetologia doi: 10.1007/s00125-013-2902-4 – volume: 348 start-page: g2867 year: 2014 ident: 2054_CR20 publication-title: BMJ doi: 10.1136/bmj.g2867 – volume: 26 start-page: 47 issue: 2_suppl year: 2019 ident: 2054_CR23 publication-title: Eur J Prev Cardiol doi: 10.1177/2047487319880041 – volume: 96 start-page: 392 issue: 3 year: 2011 ident: 2054_CR35 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2011.06.003 – volume: 96 start-page: 211 issue: 2 year: 2012 ident: 2054_CR39 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2011.12.004 – volume: 346 start-page: 393 year: 2002 ident: 2054_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa012512 – ident: 2054_CR21 doi: 10.1002/14651858.CD012661.pub2. – volume: 7 start-page: 267 issue: 4 year: 2019 ident: 2054_CR24 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30058-0 – volume: 90 start-page: 100 issue: 1 year: 2010 ident: 2054_CR25 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2010.06.008 – volume: 7 start-page: e014953 issue: 8 year: 2017 ident: 2054_CR38 publication-title: BMJ Open doi: 10.1136/bmjopen-2016-014953 – volume: 7 start-page: e017184 year: 2017 ident: 2054_CR13 publication-title: BMJ Open doi: 10.1136/bmjopen-2017-017184 – ident: 2054_CR31 – ident: 2054_CR28 – volume: 34 start-page: 55 issue: 2 year: 2017 ident: 2054_CR3 publication-title: Pract Diabetes doi: 10.1002/pdi.2080 – volume: 379 start-page: 2279 issue: 9833 year: 2012 ident: 2054_CR26 publication-title: Lancet doi: 10.1016/S0140-6736(12)60283-9 – volume-title: NHS England impact analysis of implementing NHS diabetes prevention programme, 2016 to 2021 year: 2016 ident: 2054_CR27 – volume: 31 start-page: 854 year: 2008 ident: 2054_CR8 publication-title: Diabetes Care doi: 10.2337/dc07-2162 – volume: 387 start-page: 1513 issue: 10027 year: 2016 ident: 2054_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(16)00618-8 – volume: 14 start-page: 1 issue: 1 year: 2016 ident: 2054_CR40 publication-title: BMC Med doi: 10.1186/s12916-016-0570-1 – ident: 2054_CR14 – volume-title: PH38: type 2 diabetes: prevention in people at high risk. NICE guideline PH38 year: 2012 ident: 2054_CR17 – ident: 2054_CR12 |
| SSID | ssj0025774 |
| Score | 2.3876426 |
| Snippet | Background
Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry... Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry to these... Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention programmes. Entry... Abstract Background Type 2 diabetes (T2D) is common and increasing in prevalence. It is possible to prevent or delay T2D using lifestyle intervention... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 184 |
| SubjectTerms | Biomedicine Blood Glucose Blood pressure Blood tests Cohort analysis Cohort Studies Criteria Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - prevention & control Diagnosis Disease prevention England - epidemiology EXTEND Glucose Glycated Hemoglobin Health risks Hemoglobin Humans Hyperglycemia Impact prediction Insulin Laboratories Medicine Medicine & Public Health Non-insulin treated type 2 diabetes Population Pre-diabetes Prevention Progression Research Article Risk Risk factors Survival Thresholds Type 2 diabetes |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Lb9YwDI_QhBAXxJvCgCAhcYBqbdo8yu1jYtoBJg4g7RaleWiVoJ2-duxv4b_FTh98HQIuXHponKq1Hcdu7J8Jecm5LMuCmdTz4NOyNjY1rvKpcoqVxucsqyO6_gd5cqJOT6tPO62-MCdshAceGXdgpBCutry2uUEsLVMEExwXVkEIVVQRbDuT1RxMTaEWB69mLpFR4qCHXS3HZFsInRk4KenlahuKaP2_2-SdTelqwuSVU9O4GR3dJrcmL5Juxre_Q6759i658XE6J79HfhyedWABaBfocb3JLR1AZD2eNFFwUmkTq3NjhRNtloqsnpqBInwxxXxznIv_Zymj8_9ZalpHm50U9PiwZfR8QoPqWjplfX3z_VtqKDbh3Q40ItneJ1-O3n8-PE6nJgyphaU5wLXE7KiqLDNvhMx8qK2xoRZOOqcyX3JZ-KBMHqwJwrsgZPAIspY55kLpigdkr-1a_4hQEwonlbUBUcSEL-rc2jKrFecWdCKXCclnmWg7IZRjo4yvOkYqSuhRjhrkqKMc9WVCXi9zzkd8jr9Sv0NRL5SIrR1vgMbpSeP0vzQuIc9RUfRYqLpYCL2B2IuB9ymrhLyKFGgj4AOAX2OpA7AB0bZWlPsrSljbdj08K6OebEuvGS4v7ERRJOTFMowzMV-u9d0F0ogCg-MMmPpw1N3lowvwgJngPCFypdUrrqxH2uYsIo8rhKdUWULezPr_67X-zPXH_4PrT8hNFtcvGvZ9sjdsL_xTct1-H5p--yyu_p93KmAY priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwELagINQL-xIoYCQkDhA1m5dwe1RUPUCF2NSb5XihkWhSvaT0t_BvmXEWmrJIcHmH5_HT82TWeOYbQp4yJooiz3TsmHdxUWkTa1u6WFqZFdqlWVIFdP03Yn9fHhyU78amsG6qdp-uJIOlDmot-XYHninFgllIfzMINOLTi-QSuDuJAxvef_g8p1kMIpqpPea3-xYuKCD1_2qPzzik88WS525MgyPavfZ_R7hOro6BJ10NknKDXHDNTXLl7Xi1fot83zlswWjQ1tO9apUa2sNT7vByikJcS-vQ0Buaomg9N3F1VPcUEY8plqjjXnylSzM6vdKlurG0PlO1Hn5sXj0eAaTaho6FYkeue0k1xbm9654G8Nvb5NPu6487e_E4tyE2oM09fBZYUFUWReI0F4nzldHGV9wKa2XiCiZy56VOvdGeO-u58A5x2RKbWV_Y_A7ZaNrG3SNU-9wKaYxH4DHu8io1pkgqyZgBMUpFRNLpUSozgprjbI2vKiQ3kquB5wp4rgLP1WlEns97jgdIj79Sv0IJmSkRjjt80a6_qFG7lRac28qwyqQaAd907rW3jBsJeX5e8og8RvlSQ2_rbFTUCtK1DAJWUUbkWaBAswIHAH4N3RHABgToWlBuLSjBHJjl8iTDajRHncpQI3F4RR6RJ_My7sQSu8a1J0jDc8ynE2Dq3UHk50PnEDRnnLGIiIUyLLiyXGnqwwBWLhHRUiYReTGpxM-_9Weu3_838gdkMwtahVZ_i2z06xP3kFw23_q6Wz8K5uEHYqdkhQ priority: 102 providerName: Springer Nature |
| Title | Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study |
| URI | https://link.springer.com/article/10.1186/s12916-021-02054-w https://www.ncbi.nlm.nih.gov/pubmed/34412655 https://www.proquest.com/docview/2574480523 https://www.proquest.com/docview/2563426107 https://pubmed.ncbi.nlm.nih.gov/PMC8377980 https://doaj.org/article/a766dbc5bc1a4511a3fafd56c8523396 |
| Volume | 19 |
| WOSCitedRecordID | wos000686770600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RSV dateStart: 20031201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagRagX3oVAWYyExAGi5ml7uaBt1apIdLUqDy0ny_GDrlSSZZPS38K_xeM42aaIXrhEynocre3P47E98w1Cr_KcZlmaiFDnRodZIWQo1FiHTLEkEzpOosKx63-k0ymbz8czf-BWe7fKTic6Ra0qCWfkuwl8FPj30_fLnyFkjYLbVZ9C4ybahLTZgHM6X2-4cmvbdIEyjOzWdm2LweXWbqATa6qEF4PFyHH2_62ZLy1NV90mr9yduiXp8O7_NuYeuuONUTxp0XMf3dDlA3T72F-3P0S_908rq0hwZfBRMYklbuzI13Bhha2tixcuyNcFSuFFH9hVY9FgYEHG4LYOdeGYFye4O-bFolR4ccmT3X2sL116UqmqxN557Ieu32GBIZfvqsGOEPcR-nJ48Hn_KPS5HEJpZ3hjnxk4WY2zLNKC0EibQgppCqKoUizSWU5TbZiIjRSGaGUINRq42iKVKJOpdBttlFWpnyAsTKook9IAGRnRaRFLmUUFy3NpoRXTAMXdoHLpic4h38YZdxseRngLBG6BwB0Q-EWA3vR1li3Nx7XSe4CVXhIout0P1eo79zOeC0qIKmReyFgACZxIjTAqJ5LZYU_HJEAvAGm8jXftFQ2f2C1cYo1YOg7QaycBqsY2wPZXGzFhuwFIuwaSOwNJqyLksLiDIfcqquZrDAboZV8MNcHtrtTVOciQFPbYke3Uxy34-0an1pBOSJ4HiA6mxaBXhiXl4tQRmDNguWRRgN52E2j9t_7d60-vb8UztJW4qQ2afwdtNKtz_Rzdkr-aRb0aOcXgnmyENvcOprOTkTt_sW-zD8ezb_bt5NPXP54Zc-o |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELZKQcCF92OhUCOBOJRVd727toOEUChUqZpWHIqUm_H6QSPBbsimRPwU_gS_EY_3kW4RvfXAJYd4bMWTeXjsmW8Qep5lLE0TIkOTWROmuVSh1AMTcs1JKk1Motyj64_Z4SGfTAYf19DvthYG0ipbm-gNtS4V3JFvE1gU8PeTt7PvIXSNgtfVtoVGLRb75ufShWzVm7337v99Qcjuh6OdUdh0FQiVk7WF-0wh3WeQppGRlEXG5koqm1PNtOaRSTOWGMtlbJW01GhLmTWAGhZpom2qE7fuJXTZ2XEGwR6brAK8zJ2l2sIcTrcr50tjSPF1ATtxR6Nw2XN-vkfA357glCs8m6Z55q3Wu8Ddm_8b826hG81hGw9r7biN1kxxB109aNIJ7qJfO8elM5S4tHiUD2OFF06yK3iQw-4sj6e-iNkXguFpV7hWYbnAgPKMIS0f5sI1Nia4vcbGstB4eipT3y_Wjc4a0KyywE1y3DdTvcYSQ6_i-QJ7wN976NOFMOY-Wi_KwjxEWNpEM66UBbA1apI8ViqNcp5lyqlOzAIUt0IkVAPkDv1Evgof0HEqasETTvCEFzyxDNBWN2dWw5icS_0OZLOjBAhy_0U5_yIaiyYko1TnKstVLAHkTiZWWp1RxZ2YJQMaoE2QbFHX83aGVAxdiErcIZ0NAvTSU4ApdRtw_KorQhwbAJSsR7nRo3QmUPWHW7EXjQmuxErmA_SsG4aZkFZYmPIEaGgCdwiRY-qDWtm6TScuUCA0ywLEemrY40p_pJgee4B2DiiePArQq1ZhVz_r31x_dP4uNtG10dHBWIz3Dvcfo-vEmxXwchtofTE_MU_QFfVjMa3mT71RwujzRSvyH_3tzmo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFLagoIoL-xIo1EhIHCBqFm_DbSiMiiijSizqzXK80EiQjCYp_S38W_ychUlZJMQlh_g5il_eGr_3GaEnlHJC8kzFljobk0LpWJmZjYURGVE2zZIioOsf8uVSHB_Pjja6-EO1-7Al2fU0AEpT1e6tjOtUXLC9xnupFIpnfSqc-aAjPruILhEopId8_f2nMeWiProZWmV-O2_ijgJq_6-2ecM5nS-cPLd7GpzS4tr_L-c6utoHpHjeSdANdMFWN9H2u37L_Rb6vn9Se2OCa4cPinmqceu_fgObVtjHu7gMjb6hWQqXY3NXg1WLAQkZQ-k6zIVfvTjDw69erCqDy41q9vCwcXTVA0vVFe4LyL7a5gVWGM7zXbc4gOLeRh8Xrz_sH8T9eQ6x9lre-iuBQqsZIYlVjCfWFVppVzDDjRGJJZTn1gmVOq0cs8Yx7izgtSUmM46Y_A7aqurK3kNYudxwobUDQDJm8yLVmiSFoFR78Up5hNLhs0rdg53DmRtfZEh6BJMdz6XnuQw8l2cRejbOWXVQH3-lfgnSMlICTHe4Ua8_y17rpeKMmULTQqcKgOBU7pQzlGnh8_98xiK0C7Imu57X0djIuU_jMh_I8lmEngYKMDd-AZ5fXdeEZwMAd00odyaU3kzo6fAgz7I3U43MQFPhUIs8Qo_HYZgJpXeVrU-BhuWQZyeeqXc78R8XnftgOmOURohPFGPClelIVZ4EEHMBSJciidDzQT1-vtafuX7_38h30fbRq4U8fLN8-wBdyYKCgWPYQVvt-tQ-RJf1t7Zs1o-C1fgBBcpwTQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Choice+of+HbA1c+threshold+for+identifying+individuals+at+high+risk+of+type+2+diabetes+and+implications+for+diabetes+prevention+programmes%3A+a+cohort+study&rft.jtitle=BMC+medicine&rft.au=Rodgers%2C+Lauren+R&rft.au=Hill%2C+Anita+V&rft.au=Dennis%2C+John+M&rft.au=Craig%2C+Zoe&rft.date=2021-08-20&rft.pub=BioMed+Central+Ltd&rft.issn=1741-7015&rft.eissn=1741-7015&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12916-021-02054-w&rft.externalDocID=A675243579 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |